

Form PTO-1449 (modified)		Atty. Docket No.: CLFR:190US	Serial No.: 09/714,692
<b>List of Patents and Publications for Applicant's</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <small>(Use several sheets if necessary)</small>			
<b>U.S. Patent Documents</b> <i>See Page 1</i>		<b>Foreign Patent Documents</b> <i>See Page 1</i>	<b>Other Art</b> <i>See Page 1</i>

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>Bob</i>	C1	Bale <i>et al.</i> , "Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress," <i>Nat. Genet.</i> , 24:410-414, 2000.
<i>Bob</i>	C2	Du Cros, "Fibroblast growth factor influences the development and cycling of murine hair follicles," <i>Develop. Biol.</i> , 156:444-453, 1993.
<i>Bob</i>	C3	Slominski <i>et al.</i> , "The skin produces urocortin," <i>J. Clin. Endocrinol. Metab.</i> , 85:815-823, 2000.
<i>Bob</i>	C4	Society for Neuroscience Abstracts, 29 <sup>th</sup> Annual Meeting, Miami Beach, FL, Volume 25, Part 1, p. 156, 1999.
<i>Bob</i>	C5	Tjuvajcv <i>et al.</i> , "Anti-Neoplastic Properties of Human Corticotropin Releasing Factor: Involvement of the Nitric Oxide Pathway," <i>In Vivo</i> , 12:1-10, 1998.

55055792.1

EXAMINER: *Bridget Bunner*

DATE CONSIDERED:

11/9/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.